Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 6, 2009, Pages 423-430

  Bo, S ^a   Ciccone, G ^b   Baldi, I ^b   Gambino, R ^a   Mandrile, C ^a   Durazzo, M ^a   Gentile, L ^c   Cassader, M ^a   Cavallo Perin, P ^a   Pagano, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Hospital of Asti   (Italy)

Author keywords

C reactive protein; Metabolic syndrome; Visfatin; Waist circumference

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIET RESTRICTION; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CYTOKINES; DIET; EXERCISE; FASTING; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATIVE STRESS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE;

EID: 67349087908     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.09.001     Document Type: Article

References (41)

1. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
2. Curat C.A., Wegner V., Sengenès C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 (2006) 744-747
3. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
4. Varma V., Yao-Borengasser A., Rasouli N., Bodles A.M., Phanavanh B., Lee M.J., et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipid and inflammation. J Clin Endocrinol Metab 92 (2007) 666-672
5. Hug C., and Lodish H.F. Visfatin: a new adipokine. Science 307 (2005) 366-367
6. Chen M.P., Chung F.M., Chang D.M., Tsai J.C.R., Huang H.F., Shin S.J., et al. Elevated plasma levels of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
7. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91 (2006) 3165-3170
8. Bermejo A.L., Chico-Julià B., Fernandez-Balsells M., Recasens M., Esteve E., Casamitjana R., et al. Serum visfatin increases with progressive ß-cell deterioration. Diabetes 55 (2006) 2871-2875
9. Jian W.X., Luo T.H., Gu Y.Y., Zhang H.L., Zheng S., Dai M., et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 23 (2006) 967-973
10. Hammarstedt A., Pihlajamaki J., Rotter Sopasakis V., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91 (2006) 1181-1184
11. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., and Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91 (2006) 1578-1581
12. Manco M., Fernandez-Real J.M., Equitani F., Vendrell J., Valera Mora M.E., Nanni G., et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 92 (2007) 483-490
13. Krzyzanowska K., Mittermayer F., Krugluger W., Kopp H.P., and Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity 14 (2006) 1886-1889
14. Haider D.G., Pleiner J., Francesconi M., Wiesinger G.F., Müller M., and Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 91 (2006) 4702-4704
15. Frydelund-Larsen L., Akerstrom T., Nielsen S., Keller P., Keller C., and Pedersen B.K. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. Am J Physiol Endocrinol Metab 292 (2007) E24-E31
16. Ognjanovic S., and Bryant-Greenwood G.D. Pre-B cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 187 (2002) 1051-1058
17. Jia S.H., Parodo J., Kapus A., Kapus A., Fan L., Rotstein O.D., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113 (2004) 1318-1327
18. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., and Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B cell colony-enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26 (2001) 107-117
19. Kralisch S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289 (2005) E586-E590
20. Kralish S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185 (2005) R1-R8
21. Otero M., Lago R., Gomez R., Lago F., Dieguez C., Gómez-Reino J.J., et al. Changes in fat-derived hormones plasma concentrations: adiponectin, leptin, resistin and visfatin in rheumatoid arthritis subjects. Ann Rheum Dis 65 (2006) 1198-1201
22. Tan B.K., Chen J., Digby J.E., Keay S.D., Kennedy R., and Randeva H.S. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adypocites in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 91 (2006) 5022-5028
23. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 451-458
24. Bo S., Ciccone G., Baldi C., Benini L., Dusio F., Forestiere G., et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med 22 (2007) 1695-1703
25. Bo S., Gentile L., Ciccone G., Baldi C., Benini L., Dusio F., et al. The metabolic syndrome and high C-reactive protein: prevalence and difference by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 21 (2005) 515-524
26. National Institute of Health. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
28. Huber P.J. Robust estimation of a location parameter. Ann Math Stat 35 (1964) 73-101
29. Beaton A., and Tukey J. The fitting of power series, meaning polynomials, illustrated on band-spectroscopic data. Technometrics 16 (1974) 146-185
30. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28 (2005) 888-894
31. Slentz C.A., Duscha B.D., Johnson J.L., Ketchum K., Aiken L.B., Samsa G.P., et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity. Arch Intern Med 164 (2004) 31-39
32. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27 (2004) 2444-2449
33. Chen C.C., Li T.C., Li C.I., Liu C.S., Lin W.Y., Wu M.T., et al. The relationship between visfatin levels and anthopometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56 (2007) 1216-1220
34. Sun G., Bishop J., Khalili S., Vasdev S., Gill V., Pace D., et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 85 (2007) 399-404
35. Ingelsson E., Larson M.G., Fox C.S., Yin X., Wang T.J., Lipinska I., et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 30 (2007) 1270-1280
36. Sandeep S., Velmurugan K., Deepa R., and Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56 (2007) 565-570
37. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178 (2007) 1748-1758
38. Dahl T.B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis. Possible role in inflammation and plaque destabilization. Circulation 115 (2007) 972-980
39. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
40. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
41. Ross R., Dagnone D., Jones P.J.H., Smith H., Paddags A., Hudson R., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med 133 (2000) 92-103